No Data
Omnicell (OMCL) Upgraded to Buy: What Does It Mean for the Stock?
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
Goldman Sachs Siasun Robot&Automation deep research (3): Humanoid robots may be nearing mass production, with turning points emerging in three areas.
Humanoid robots are rapidly developing, but overall technology has not yet met the requirements for large-scale application in the industrial or Consumer sectors. Goldman Sachs believes that the turning point for humanoid robot technology may occur in three areas: solving multiple general tasks, high success rates and sustained robustness, and rapid reasoning. Currently, the development of humanoid robots still faces some obstacles, such as the lack of original data needed for training.
Piper Sandler Maintains Omnicell(OMCL.US) With Buy Rating, Maintains Target Price $69
Analysts Are Bullish on Top Healthcare Stocks: Penumbra (PEN), Omnicell (OMCL)
Omnicell's (NASDAQ:OMCL) Earnings Offer More Than Meets The Eye
